PAPP-A and free ß-hCG stability in first trimester serum using PerkinElmer AutoDELFIA® and DELFIA® Xpress systems

Prenatal Diagnosis

Volumn 30, Issue 2, 2010, Pages 127-132

  Cowans, Nicholas J ^a   Stamatopoulou, Anastasia ^a   Hellström, Johanna ^b   Mäkelä, Minna Maarit ^b   Spencer, Kevin ^a  

^a KING GEORGE HOSPITAL   (United Kingdom)

^b Research and Development   (Finland)

Author keywords

First trimester; Free beta hCG; PAPP A; Screening; Stability

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; MARKER; PREGNANCY ASSOCIATED PLASMA PROTEIN A; BIOLOGICAL MARKER;

ANALYZER; ARTICLE; BLOOD; BLOOD SAMPLING; CHROMOSOME ABERRATION; CONTROLLED STUDY; FIRST TRIMESTER PREGNANCY; HUMAN; MATERNAL SERUM; PRIORITY JOURNAL; REFRIGERATOR; RISK ASSESSMENT; ROOM TEMPERATURE; STORAGE; TEMPERATURE; ADULT; FEMALE; LABORATORY DIAGNOSIS; PREGNANCY; PROTEIN STABILITY;

ADULT; BIOLOGICAL MARKERS; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; FEMALE; HUMANS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PROTEIN STABILITY; SPECIMEN HANDLING; TEMPERATURE;

EID: 75649126262     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.2423     Document Type: Article

References (31)

1. Anderson G, Scott M. 1991. Determination of product shelf life and activation energy for five drugs of abuse. Clin Chem 37: 398-402.
2. Beaman JM, Akhtar N, Goldie DJ. 1996. Downs syndrome screening using free beta-hCG-instability can significantly increase the downs risk estimate. Ann Clin Biochem 33: 525-529.
3. Bersinger NA, Marguerat P, Pescia G, Schneider H. 1995. Pregnancyassociated plasma protein A (PAPP-A): measurement by highly sensitive and specific enzyme immunoassay, importance of firsttrimester serum determinations, and stability studies. Reprod Fertil Dev 7: 1419-1423.
4. Bonno M, Oxvig C, Kephart GM, et al. 1994. Localization of pregnancy-associated plasma protein-A and colocalization of pregnancy-associated plasma protein-A messenger ribonucleic acid and eosinophil granule major basic protein messenger ribonucleic acid in placenta. Lab Invest 71: 560-566.
5. Cole LA. 1997. Immunoassay of human chorionic gonadotropin, its free subunits, and metabolites. Clin Chem 43: 2233-2243.
6. Cuckle HS, Jones RG. 1994. Maternal serum free beta human chorionic gonadotrophin level: the effect of sample transportation. Ann Clin Biochem 31: 97-98.
7. Cuckle HS, Jones RG. 1995. Posting maternal blood samples for free beta-human chorionic gonadotrophin testing. Prenat Diagn 15: 879-880.
8. Kardana A, Cole LA. 1997. The stability of hCG and free beta-subunit in serum samples. Prenat Diagn 17: 141-147.
9. Knight GJ, Cole LA. 1991. Measurement of choriogonadotropin free beta-subunit: an alternative to choriogonadotropin in screening for fetal Down's syndrome? Clin Chem 37: 779-782.
10. Lambert-Messerlian GM, Eklund EE, Malone FD, Palomaki GE, Canick JA, D'Alton ME. 2006. Stability of first- and secondtrimester serum markers after storage and shipment. Prenat Diagn 26: 17-21.
11. Macri JN, Kasturi RV, Krantz DA, et al. 1990. Maternal serum Down syndrome screening: free beta-protein is a more effective marker than human chorionic gonadotropin [see comments]. Am J Obstet Gynecol 163: 1248-1253.
12. Masse J, Forest JC, Moutquin JM, Degrandpre P. 1997. Effect of repeated freeze-thaw cycles on maternal serum biological markers for the detection of fetal trisomies. Clin Biochem 30: 527-530.
13. Muller F, Doche C, Ngo S, et al. 1999. Stability of free beta-subunit in routine practice for trisomy 21 maternal serum screening. Prenat Diagn 19: 85-86.
14. Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O. 2005. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol 25: 221-226.
15. Oxvig C, Sand O, Kristensen T, Gleich GJ, Sottrup-Jensen L. 1993. Circulating human pregnancy-associated plasma protein-A is disulfide-bridged to the proform of eosinophil major basic protein. J Biol Chem 268: 12243-12246.
16. Perni SC, Predanic M, Kalish RB, Chervenak FA, Chasen ST. 2006. Clinical use of first-trimester aneuploidy screening in a United States population can replicate data from clinical trials. Am J Obstet Gynecol 194: 127-130.
17. Qin QP, Christiansen M, Pettersson K. 2002. Point-of-care time-resolved immunofluorometric assay for human pregnancyassociated plasma protein A: use in first-trimester screening for Down syndrome. Clin Chem 48: 473-483.
18. Sancken U, Bahner D, Free beta-hcg, Maternal serum screening, Thermal, and instability. 1995. The effect of thermal instability of intact human chorionic gonadotropin (ihcg) on the application of its free beta-subunit (free beta-hcg) as a serum marker in down syndrome screening. Prenat Diagn 15: 731-738.
19. Spencer K. 1991. Evaluation of an assay of the free beta-subunit of choriogonadotropin and its potential value in screening for Down's syndrome [see comments]. Clin Chem 37: 809-814.
20. Spencer K. 1999. Second trimester prenatal screening for Down's syndrome using alpha-fetoprotein and free beta hCG: a seven year review. Br J Obstet Gynaecol 106: 1287-1293.
21. Spencer K. 2007. Aneuploidy screening in the first trimester. Am J Med Genet C Semin Med Genet 145C: 18-32.
22. Spencer K, Macri JN. 1992. Early detection of Down's syndrome using free beta human choriogonadotropin. Ann Clin Biochem 29(Pt 3): 349-350.
23. Spencer K, Macri JN. 1994. The use of free beta-hCG in antenatal screening for Down's syndrome. Br J Obstet Gynaecol 101: 175-176.
24. Spencer K, Aitken D. 2004. Factors affecting women's preference for type of prenatal screening test for chromosomal anomalies. Ultrasound Obstet Gynecol 24: 735-739.
25. Spencer K, Coombes EJ, Mallard AS, Ward AM. 1992. Free beta human choriogonadotropin in Down's syndrome screening: a multicentre study of its role compared with other biochemical markers. Ann Clin Biochem 29(Pt 5): 506-518.
26. Spencer K, Macri JN, Carpenter P, Anderson R, Krantz DA. 1993. Stability of intact chorionic gonadotropin (hCG) in serum, liquid whole blood, and dried whole-blood filter-paper spots: impact on screening for Down syndrome by measurement of free beta- hCG subunit. Clin Chem 39: 1064-1068.
27. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. 1999. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 13: 231-237.
28. Stevenson HP, Leslie H, Sheridan B. 1993. Serum free beta-human chorionic gonadotrophin concentrations increase in unseparated blood specimens. Ann Clin Biochem 30: 99-100.
29. Stone SJ, Henley R. 1995. The stability of blood samples for the measurement of the free beta subunit of chorionic gonadotrophin. Prenat Diagn 15: 95-96.
30. Wald NJ, Densem JW, Stone R, Cheng R. 1993. The use of free β-hCG in antenatal screening for Down syndrome. Br J Obstet Gynaecol 100: 550-557.
31. Zimmermann R, Keller PJ, Huch A. 1994. Increased maternal serum free beta human chorionic gonadotrophin concentrations in Down's pregnancies: an artefactual finding? Br J Obstet Gynaecol 101: 257-258.